glp-1 agonist dpp 4 inhibitor Role of DPP-4 Inhibitors in Clinical Practice GLP-1 receptor agonists and DPP-4
Description
Recent reports indicate that funding for diabetes research has increased by over 25% in the past year, reflecting a commitment to addressing these pressing health issues
Starting July 1, 2026, Medicare covers these GLP-1 drugs: Foundayo (tablet) Wegovy (injection or tablet) Zepbound (KwikPen only
You will need bacteriostatic water (BAC water containing 0.9% benzyl alcohol), sterile syringes, alcohol swabs, and proper refrigeration immediately available
According to American Diabetes Association and American College of Cardiology/American Heart Association guidelines, patients with dyslipidemia requiring significant LDL-C reduction will still need statin therapy or other dedicated lipid-lowering medications
